Target intelligence / Profile preview

Mobiluncus species (Mobiluncus spp.)

Target
Mobiluncus spp.
Molecular classification
Bacteria, Actinomycetota, Gram-variable anaerobe
01

Overview

Mobiluncus species are anaerobic, motile, gram-variable, curved rod-shaped bacteria that are significant components of the polymicrobial flora associated with bacterial vaginosis (BV) (StatPearls, 2023). The genus primarily includes Mobiluncus curtisii and Mobiluncus mulieris, which are frequently isolated from the vaginal tracts of women with symptomatic BV but are rarely found in healthy individuals (CDC, 2021). These organisms contribute to the pathogenesis of BV by producing metabolic byproducts like malic acid and various amines, which contribute to the characteristic vaginal discharge and odor (Journal of Medical Microbiology, 2005). In clinical practice, the identification of Mobiluncus on a Gram stain is a specific marker used in the Nugent scoring system for diagnosing BV (PubMed, 2016). While metronidazole is a standard treatment for BV, Mobiluncus species often demonstrate decreased susceptibility to this agent, frequently requiring clindamycin for effective clearance (American Journal of Obstetrics and Gynecology, 2010). Their presence is also linked to more severe reproductive health complications, including pelvic inflammatory disease and increased risk of preterm labor (NIH, 2022).

Other names
Mobiluncus curtisiiMobiluncus mulierisAnaerobic curved rods
02

Mechanism of action

Antibiotics targeting Mobiluncus species typically inhibit DNA synthesis via nitroreduction (e.g., metronidazole) or inhibit protein synthesis by binding to the 50S ribosomal subunit (e.g., clindamycin) (StatPearls, 2023; PubMed, 2010).

03

Biological functions

Anaerobic metabolismBacterial motilityBiofilm formationAmine production
04

Disease associations

Bacterial vaginosis (StatPearls, 2023)Pelvic inflammatory disease (NIH, 2022)Preterm birth (CDC, 2021)Chorioamnionitis (PubMed, 2010)
05

Safety considerations

Antibiotic resistance (especially to metronidazole) (PubMed, 2010)Recurrence of bacterial vaginosis (StatPearls, 2023)Disruption of commensal Lactobacillus flora (CDC, 2021)
06

Interacting drugs

Metronidazole

3 more in the full profile.

07

Biomarkers

Nugent score (PubMed, 2016)Amsel criteria (StatPearls, 2023)16S rRNA sequencing (Nature, 2011)Vaginal pH > 4.5 (CDC, 2021)

Beyond the preview

Go deeper on Mobiluncus species (Mobiluncus spp.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mobiluncus species (Mobiluncus spp.).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call